ATE231723T1 - Verwendung von pharmazeutischen wirkstoffen zur behandlung von krankheitssymptomen neurologischer erkrankungen und etiologisch verwandter symptomenkomplexe - Google Patents
Verwendung von pharmazeutischen wirkstoffen zur behandlung von krankheitssymptomen neurologischer erkrankungen und etiologisch verwandter symptomenkomplexeInfo
- Publication number
- ATE231723T1 ATE231723T1 AT92907973T AT92907973T ATE231723T1 AT E231723 T1 ATE231723 T1 AT E231723T1 AT 92907973 T AT92907973 T AT 92907973T AT 92907973 T AT92907973 T AT 92907973T AT E231723 T1 ATE231723 T1 AT E231723T1
- Authority
- AT
- Austria
- Prior art keywords
- disease
- symptomology
- neurological diseases
- agents
- present
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/618—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate
- A61K31/621—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate having the hydroxy group in position 2 esterified, e.g. benorylate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Microbiology (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Reproductive Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Food Science & Technology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US66056191A | 1991-02-22 | 1991-02-22 | |
PCT/US1992/001365 WO1992014456A1 (en) | 1991-02-22 | 1992-02-21 | Use of pharmaceutical compounds in the treatment of symptoms of disorders related to neurological diseases and etiologically related symptomology |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE231723T1 true ATE231723T1 (de) | 2003-02-15 |
Family
ID=24650025
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT92907973T ATE231723T1 (de) | 1991-02-22 | 1992-02-21 | Verwendung von pharmazeutischen wirkstoffen zur behandlung von krankheitssymptomen neurologischer erkrankungen und etiologisch verwandter symptomenkomplexe |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP0572560B1 (de) |
JP (1) | JPH06502184A (de) |
AT (1) | ATE231723T1 (de) |
AU (1) | AU668682B2 (de) |
CA (1) | CA2104594C (de) |
DE (1) | DE69232909D1 (de) |
WO (1) | WO1992014456A1 (de) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5668117A (en) * | 1991-02-22 | 1997-09-16 | Shapiro; Howard K. | Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments |
EP0604641B1 (de) * | 1992-06-30 | 2002-03-20 | SHAPIRO, Howard, K. | Verwendung einer kombination bestehend aus einem aminderivat oder aminverwandten derivat der benzoesäure und einem amino-polysaccharide zur herstellung eines medikaments fuer die behandlung von entzündlichen erkrankungen |
US5840294A (en) * | 1993-03-29 | 1998-11-24 | Queen's University At Kingston | Method for treating amyloidosis |
US20040208875A1 (en) | 1995-03-15 | 2004-10-21 | Queen's University At Kingston | Method for treating amyloidosis |
EP1060750B1 (de) * | 1993-03-29 | 2005-12-07 | Queen's University At Kingston | Propan-1,3-disulphonsäure und deren pharmazeutisch akzeptable Salze zur Behandlung von Amyloidosis |
JP3583239B2 (ja) * | 1996-01-25 | 2004-11-04 | 花王株式会社 | 皮膚外用剤 |
US5939451A (en) * | 1996-06-28 | 1999-08-17 | Hoffmann-La Roche Inc. | Use of sulfonamides |
AU6518598A (en) * | 1997-03-28 | 1998-10-22 | Otsuka Pharmaceutical Co., Ltd. | Age production inhibitory composition comprising a maillard reaction inhibitor and vitamin b6 |
US5981168A (en) * | 1998-05-15 | 1999-11-09 | The University Of British Columbia | Method and composition for modulating amyloidosis |
WO2000027376A2 (de) * | 1998-10-26 | 2000-05-18 | Michael Schedler | Verwendung von thiolverbindungen, oxidoreduktasen und/oder hydrolasen zur behandlung des tinnitus, insbesondere des chronischen tinnitus |
US6562836B1 (en) | 1999-05-24 | 2003-05-13 | Queen's University Of Kingston | Methods and compounds for inhibiting amyloid deposits |
US6531478B2 (en) | 2000-02-24 | 2003-03-11 | Cheryl P. Kordik | Amino pyrazole derivatives useful for the treatment of obesity and other disorders |
JP2001247458A (ja) * | 2000-03-08 | 2001-09-11 | Hamari Chemicals Ltd | トラネキサム酸亜鉛化合物を含む糖尿病治療剤 |
PE20021046A1 (es) * | 2000-09-30 | 2002-12-14 | Gruenenthal Chemie | Sulfonilguanidina que tiene afinidad al punto de fijacion de gabapentina |
US7199122B2 (en) | 2001-10-02 | 2007-04-03 | Fox Chase Cancer Center | Methods for inhibiting angiogenesis |
FR2848452B1 (fr) * | 2002-12-12 | 2007-04-06 | Aventis Pharma Sa | Application des inhibiteurs de recapture intestinale des acides biliaires pour la prevention et le traitement de la maladie d'alzheimer |
CA2528627A1 (en) * | 2003-06-23 | 2005-01-06 | Neurochem (International) Limited | Treatment of protein aggregation disorders |
CA2592320C (en) | 2004-12-22 | 2015-11-24 | Neurochem (International) Limited | Methods and compositions for treating amyloid-related diseases |
FR2883873B1 (fr) * | 2005-03-31 | 2009-07-10 | Pharmamens Sarl | Inhibiteurs d'age |
ES2352801T3 (es) | 2005-12-22 | 2011-02-23 | Kiacta Sàrl | Tratamiento de nefropatía diabética. |
CA2666246C (en) | 2006-10-12 | 2013-12-31 | Bellus Health (International) Limited | Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid |
EP2322163A1 (de) * | 2009-11-03 | 2011-05-18 | Pharnext | Neue therapeutische Ansätze zur Behandlung von Alzheimer-Krankheit |
ES2936094T3 (es) * | 2016-06-13 | 2023-03-14 | Syneurx Int Taiwan Corp | Cocristales de benzoato de sodio y usos de los mismos |
RU2022101542A (ru) * | 2016-06-13 | 2022-02-03 | Сайньюрекс Интернэшнл (Тайвань) Корп. | Сокристаллы бензоата лития и их применения |
US20210270852A1 (en) * | 2018-06-15 | 2021-09-02 | The Regents Of The University Of California | Methods of Detecting Neuroaxonal Dystrophy Disorders Associated with Vitamin E Deficiency and Uses Thereof |
CA3141431A1 (en) * | 2019-06-12 | 2020-12-17 | Alfred N. Fonteh | Methods for evaluation and treatment of alzheimer's disease and applications thereof |
EP4257139A3 (de) * | 2022-04-07 | 2023-12-13 | Mitos Therapeutics Inc. | Zusammensetzung zur verbesserung, prävention oder behandlung von muskelerkrankungen mit verbindungen auf sulfonamidbasis |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3895107A (en) * | 1970-04-15 | 1975-07-15 | Morrison L M | CSA and CSC in man and mammals to inhibit atherosclerosis and the recurrence of cardiovascular incidents in atherosclerotic mammals |
US4039388A (en) * | 1976-06-04 | 1977-08-02 | The United States Of America As Represented By The Government | Diagnostic test for Niemann-Pick disease |
GB1551416A (en) * | 1976-08-27 | 1979-08-30 | Beecham Group Ltd | Long chain dioxy hypolipidaemics |
US4309534A (en) * | 1979-02-15 | 1982-01-05 | University Of Delaware | Renatured chitosan and process of making same |
US4665069A (en) * | 1985-04-02 | 1987-05-12 | Barnett Rosenberg | Analgesic composition and method of relieving pain |
US4638014A (en) * | 1985-08-26 | 1987-01-20 | Research Corporation | Anticonvulsant method and formulations |
US4595586A (en) * | 1985-08-30 | 1986-06-17 | Eli Lilly And Company | Moisturizing lotion |
US4812447A (en) * | 1985-10-22 | 1989-03-14 | City Of Hope | Method for the treatment of nervous system degeneration |
US4889722A (en) * | 1985-12-16 | 1989-12-26 | Ethicon, Inc. | Method for inhibiting post-surgical adhesion formation by the topical administration of tissue plasminogen activator |
US4923696A (en) * | 1987-05-04 | 1990-05-08 | Baylor College Of Medicine | Method to prepare a neurotrophic composition |
DK536987A (da) * | 1987-10-14 | 1989-04-15 | Ferring Farma Lab | Anvendelse af 5-aminosalicylsyre (5-asa) til fremstilling af et farmaceutisk praeparat til anvendelse ved reperfusionsbehandling |
ATE135206T1 (de) * | 1988-08-12 | 1996-03-15 | Astra Ab | Arylalkylamine und -amide mit krampflösender und nervenschützender wirkung |
US5013769A (en) * | 1988-08-22 | 1991-05-07 | Medipro Sciences Limited | Method of making a hydrogel-forming wound dressing or skin coating material |
-
1992
- 1992-02-21 CA CA002104594A patent/CA2104594C/en not_active Expired - Fee Related
- 1992-02-21 DE DE69232909T patent/DE69232909D1/de not_active Expired - Lifetime
- 1992-02-21 AT AT92907973T patent/ATE231723T1/de not_active IP Right Cessation
- 1992-02-21 EP EP92907973A patent/EP0572560B1/de not_active Expired - Lifetime
- 1992-02-21 JP JP4507550A patent/JPH06502184A/ja active Pending
- 1992-02-21 WO PCT/US1992/001365 patent/WO1992014456A1/en active IP Right Grant
- 1992-02-21 AU AU15614/92A patent/AU668682B2/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
DE69232909D1 (de) | 2003-03-06 |
AU1561492A (en) | 1992-09-15 |
JPH06502184A (ja) | 1994-03-10 |
EP0572560A4 (de) | 1995-04-26 |
AU668682B2 (en) | 1996-05-16 |
CA2104594A1 (en) | 1992-08-23 |
WO1992014456A1 (en) | 1992-09-03 |
EP0572560B1 (de) | 2003-01-29 |
CA2104594C (en) | 2004-05-11 |
EP0572560A1 (de) | 1993-12-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE231723T1 (de) | Verwendung von pharmazeutischen wirkstoffen zur behandlung von krankheitssymptomen neurologischer erkrankungen und etiologisch verwandter symptomenkomplexe | |
JP6444548B2 (ja) | スルホアルキルエーテルシクロデキストリン組成物 | |
EP1372735B1 (de) | Hydroxyalkylstärke-wirkstoff-konjugate | |
DE3026398C2 (de) | ||
Saida et al. | Peripheral nerve changes induced by methyl n-butyl ketone and potentiation by methyl ethyl ketone | |
DE602004009314T2 (de) | Polysialinsäurederivate | |
BR9813373A (pt) | Composto, processo para a preparação do mesmo, composição farmacêutica, processo para a preparação da mesma, uso de um composto, e, processos para efetuar imunossupressão e para tratar ou reduzir o risco de uma doença das vias aérias obstrutiva reversìvel em um paciente | |
DE69826684T2 (de) | Kovalent gebundenes n,o-carboxymethylchitosan und seine verwendungen | |
EP0265865A2 (de) | Blutersatzmittel | |
YU70394A (sh) | Antagonisti receptora nadražujućih amino kiselina i postupak za njihovo dobijanje | |
MX172600B (es) | , "procedimiento para la produccion de una proteina biologicamente activa | |
BR9811055A (pt) | Composto , uso do mesmo, composição farmacêutica, e, processo para tratamento de doença ou condição médica mediada pelo fator xa | |
EP0346501B1 (de) | Arzneimittelzubereitung zur behandlung des immunmangels | |
ATE215967T1 (de) | Aus harn isolierte antikoagulierende verbindung | |
EP0010309B1 (de) | Mittel zur Behandlung allergischer Reaktionen | |
EP1548004A1 (de) | Niedermolekulare biologische derivate | |
Carlsson et al. | Preparation of bovine mercaptalbumin by means of covalent chromatography | |
EP1597271B1 (de) | Peptide gegen kälteunverträglichkeit hervorrufende autoantikörper und ihre verwendung | |
CN1556711A (zh) | 使用凝血酶衍生的缩氨酸治疗慢性真皮溃疡 | |
DE4221836A1 (de) | Das biochemisch aufgereinigte Mistel-Lektin (ML-1) als therapeutisch anwendbarer Immunmodulator | |
JPS60258120A (ja) | 胸腺製品の製造方法 | |
DE2448530C3 (de) | Verfahren zum Herstellen von Derivaten des Diphtherietoxins und diese enthaltende Mittel | |
BEPPU et al. | Interaction of malondialdehyde-modified bovine serum albumin and mouse peritoneal macrophages | |
CH645880A5 (de) | Synthetisches antigenaktives polypeptid, verfahren zu dessen herstellung und das polypeptid enthaltendes antigenes mittel sowie arzneimittel. | |
EP1340087B1 (de) | Verwendung intramolekular kovalent vernetzter proteine als bindepartner in immunoassays |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |